{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T10:48:52Z","timestamp":1782989332008,"version":"3.54.5"},"reference-count":16,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acromegaly management is particularly challenging when pituitary adenomas invade the cavernous sinus, limiting the likelihood of complete surgical resection. We describe a case of a 40-year-old woman with acromegaly caused by a growth hormone and prolactin co-secreting pituitary macroadenoma with bilateral cavernous sinus invasion and severe, frequent headache. Despite transsphenoidal surgery, radiotherapy, and sequential medical therapy with octreotide, cabergoline, and pegvisomant over 3 years, insulin-like growth factor 1 (IGF-1) levels remained elevated and headache burden persisted. Initiation of pasireotide long-acting release was followed by rapid normalization of IGF-1 levels and complete resolution of headache, with improvement in other acromegaly related symptoms. This case supports the potential role of pasireotide in selected patients with biochemically and clinically treatment-resistant acromegaly and contributes to the growing real-world evidence regarding its use in patients with residual disease in surgically challenging locations.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag063","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T12:35:33Z","timestamp":1771677333000},"source":"Crossref","is-referenced-by-count":0,"title":["Beyond biochemical control: headache resolution with pasireotide in a patient with acromegaly and residual tumor"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8024-0631","authenticated-orcid":false,"given":"Aishah A","family":"Ekhzaimy","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, King Saud University Medical City, King Saud University , Riyadh 11461 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, King Saud University Medical City, King Saud University , Riyadh 11461 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Alghamlas","sequence":"additional","affiliation":[{"name":"College of Medicine, King Saud University , Riyadh 11461 ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"issue":"11","key":"2026070205434444500_luag063-B1","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41574-025-01148-2","article-title":"Consensus on acromegaly therapeutic outcomes: an update","volume":"21","author":"Melmed","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2026070205434444500_luag063-B2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2026070205434444500_luag063-B3","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"2026070205434444500_luag063-B4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocr Disord"},{"key":"2026070205434444500_luag063-B5","doi-asserted-by":"crossref","first-page":"1351350","DOI":"10.3389\/fendo.2024.1351350","article-title":"Editorial: treatment outcomes, comorbidities and impact of discordant biochemical values in acromegaly","volume":"15","author":"Campana","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"2026070205434444500_luag063-B6","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1210\/clinem\/dgab874","article-title":"State of the art of patient-reported outcomes in acromegaly or GH deficiency: a systematic review and meta-analysis","volume":"107","author":"van der Meulen","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026070205434444500_luag063-B7","doi-asserted-by":"crossref","first-page":"101887","DOI":"10.1016\/j.beem.2024.101887","article-title":"Real-world value of cabergoline in the treatment of acromegaly","volume":"38","author":"Shimon","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"8","key":"2026070205434444500_luag063-B8","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1007\/s40618-023-02299-7","article-title":"Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center","volume":"47","author":"Pirchio","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2026070205434444500_luag063-B9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11154-024-09928-3","article-title":"Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis","volume":"26","author":"Biagetti","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"issue":"7","key":"2026070205434444500_luag063-B10","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s40618-023-02275-1","article-title":"Real-life data of pasireotide LAR in acromegaly: a long-term follow-up","volume":"47","author":"Urbani","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"2026070205434444500_luag063-B11","doi-asserted-by":"crossref","first-page":"luae142","DOI":"10.1210\/jcemcr\/luae142","article-title":"Rapid resolution of recalcitrant headache with pasireotide in an adult patient with acromegaly","volume":"2","author":"Dabbous","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"2","key":"2026070205434444500_luag063-B12","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","article-title":"Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study","volume":"62","author":"Shimon","year":"2018","journal-title":"Endocrine"},{"key":"2026070205434444500_luag063-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7573\/dic.2024-1-2","article-title":"Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences","volume":"13","author":"Chiloiro","year":"2024","journal-title":"Drugs Context"},{"issue":"6","key":"2026070205434444500_luag063-B14","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1210\/clinem\/dgac037","article-title":"Approach to the patient with treatment-resistant acromegaly","volume":"107","author":"Coopmans","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026070205434444500_luag063-B15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026070205434444500_luag063-B16","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/8\/luag063\/68677260\/luag063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/8\/luag063\/68677260\/luag063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T09:43:52Z","timestamp":1782985432000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag063\/8723439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":16,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag063","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"luag063"}}